Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Watch-List Update: ZIOP to Present at Bio Investor Forum

|Includes: ZIOPHARM Oncology, Inc. (ZIOP)

The University of Cash Watch-List member ZIOPHARM Oncology (Nasdaq: ZIOP) is presenting at the 10th Annual Bio Investor Forum on Tuesday October 25th, at the Palace Hotel in San Francisco, CA.

ZIOPHARM specializes in develloping and commercializing cancer therapies. ZIOP closed up 2.44% Friday at $4.19 per share and traded 577,133 shares.

The BIO Investor Forum delivers a diverse program that features corporate presentations and panel debates on, "the sweet spots and growth challenges facing the industry."

The Program Includes:

  • Public and venture-stage company presentations
  • Expert-led workshops on the latest market and investment opportunities with emphasis on drug and technology development
  • One-on-one investor meetings
  • Premier opportunity to network with industry executives and investors focused exclusively on life sciences
Audience members will include, public and private equity investors, research analysts, and industry executives focused on investment and business development.

More info about the BIO Investor Forum can be read at

About The University of Cash

The University of Cash is owned by an independant Invesor Relations and Investment Research Firm. The University of Cash specializes in providing Investor Relations services for micro-cap companies and is targeted to a younger investor audience. We pride ourselves on finding fresh and intuitive companies that could benefit investors. We believe in educating our subscribers on the companies we find and why they belong on our watch-list. Disclaimer

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Additional disclosure: disclaimer should be read in its entirety and should be fully understood before using our site, social networking profiles or joining our email list. If you do not understand this dislaimer, you should refrain from using our site, the related social networking profiles or joining our email list.